Click here to read the articles and view the interactive digital edition

Pharmaceutical Commerce - October 2025

Cencora executive Heather Zenk discusses how innovations in cold chain, data visibility, and sustainability strategies are transforming the drug delivery process.

Building Resilient, Sustainable Pharma Supply Chains

From patent cliffs and government price controls, to self-pay models and staff-model HMOs, a look at the forces that could deflate the bubble—and those factors likely to keep it afloat a while longer.

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

Advice for pharma distributors and dispensers on what they should do now in order to solidify a secure supply chain.

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead

Articles

This guide outlines a proven framework, spanning process, people, and platform, to help healthcare innovators scale AI with compliance, collaboration, and clinical impact in mind.

A Practitioner’s Guide to AI Lifecycle Management in Life Sciences

. He can be reached at nsaraceno@mjhlifesciences.com.

Launching next year, the new CMS Innovation Center initiative—known as the GENEROUS Model—aims to align Medicaid drug prices with global standards, reduce prescription spending, and strengthen the program’s long-term sustainability through fairer state purchasing and transparent pricing rules.

CMS Unveils Initiative to Cut Medicaid Drug Costs and Expand Access to Affordable Medications

Podcasts

This episode of Pharma Pulse discusses FDA’s growing National Priority Voucher initiative, fresh data on oral semaglutide’s cardiometabolic impact, and Mark Cuban’s latest drug addition that signals key shifts in innovation, access, and affordability across the pharmaceutical landscape.

Pharma Pulse: FDA Expands Priority Voucher Program, as Oral Semaglutide Shows New Benefits and Cost Plus Drugs Adds Starjemza

Lilly announced a new agreement with the Trump administration to expand access to its GLP-1 therapies, including Zepbound and orforglipron, offering the drugs to Medicare beneficiaries for $50 per month and through Medicaid programs starting in 2026.

Lilly Agreement With Trump Administration Reshapes Patient Access to GLP-1 Obesity Medicines  

A professor of food, pharma, and healthcare business at Saint Joseph’s University’s Erivan K. Haub School of Business.

Pharma’s push into direct-to-patient sales is reshaping the front end of drug distribution, but wholesalers like Cencora, McKesson, and Cardinal Health remain indispensable as the backbone of the industry’s regulated, specialty, and logistics infrastructure.

Will Pharma’s Direct-to-Patient Push Disintermediate Wholesalers?

The addition of Starjemza reinforces Mark Cuban Cost Plus Drugs' effort to expand access to affordable specialty medicines through its transparent cost-plus pricing model, while also enhancing patient support via a new partnership with Medchat.ai.

Mark Cuban Cost Plus Drug Company Adds Starjemza to Prescription Drug Portfolio 

As the three models converge, expect a bigger role for sales reps, minimal impact on incentive compensation, and a boon to the healthcare system.

The New Pharma Equation: How DTP, DTC, and DTE are Re-Wiring Healthcare Around Patients

Cencora's investment includes new automated centers in Ohio and California and a major cold chain expansion in Alabama to enhance capacity, efficiency, and supply chain resilience.

Cencora Reveals $1 Billion Investment Plan Enhancing US-Based Distribution Network 

How next-generation AI-driven traceability hubs can transform pharmaceutical serialization from a compliance requirement into a business advantage, while enabling real-time supply chain visibility, faster issue resolution, and greater operational efficiency across the global drug distribution network.

Why AI-Augmented Traceability Hubs are the Future of Pharma Serialization

Videos

In second part of his Pharma Commerce video interview, Faisal Khan, a GRC solutions expert with Vanta, urges organizations to move beyond one-time vetting toward continuous monitoring, contractual accountability, and shared responsibility for HIPAA compliance.

Featured Content

Pharmaceutical Commerce - October 2025

Building Resilient, Sustainable Pharma Supply Chains

Popping the Gross-to-Net Bubble, Part VI: The Future of Pharmaceutical Pricing

DSCSA Compliance: Milestones, More Deadlines—and the Road Ahead